Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) EBT Margin (2020 - 2025)

Foghorn Therapeutics has reported EBT Margin over the past 6 years, most recently at 239.71% for Q4 2025.

  • Quarterly results put EBT Margin at 239.71% for Q4 2025, up 44317.0% from a year ago — trailing twelve months through Dec 2025 was 251.2% (up 13204.0% YoY), and the annual figure for FY2025 was 251.2%, up 13204.0%.
  • EBT Margin for Q4 2025 was 239.71% at Foghorn Therapeutics, down from 202.0% in the prior quarter.
  • Over the last five years, EBT Margin for FHTX hit a ceiling of 77.85% in Q3 2023 and a floor of 65268.29% in Q3 2021.
  • Median EBT Margin over the past 5 years was 502.59% (2024), compared with a mean of 4636.7%.
  • Biggest five-year swings in EBT Margin: plummeted -5482639bps in 2021 and later skyrocketed 6487985bps in 2022.
  • Foghorn Therapeutics' EBT Margin stood at 3998.32% in 2021, then surged by 83bps to 690.39% in 2022, then surged by 44bps to 383.43% in 2023, then plummeted by -78bps to 682.88% in 2024, then soared by 65bps to 239.71% in 2025.
  • The last three reported values for EBT Margin were 239.71% (Q4 2025), 202.0% (Q3 2025), and 248.62% (Q2 2025) per Business Quant data.